2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes

US7956077B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Heiner Glombik · Hofheim, DE
• Christian Stapper · Mainz, DE
• Eugen Falk · Frankfurt am Main, DE
• Stefanie Keil · Frankfurt am Main, DE
• Hans-Ludwig Schaefer · Frankfurt am Main, DE
• Wolfgang Wendler · Bad Camberg, DE
• Stephanie Knieps · Pocking, DE

Key dates

• Filing date: Feb 6, 2007
• Grant date: Jun 7, 2011
• Expiry date: Feb 6, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P5/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with cyclohexylmethoxy substituents and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of formula Iwherein the various substituent R-groups are more specifically defined herein.